Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309014865> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4309014865 endingPage "vii107" @default.
- W4309014865 startingPage "vii107" @default.
- W4309014865 abstract "Abstract Current standard-of-care for glioblastoma (GBM) includes surgery followed by radiation with concurrent and adjuvant temozolomide. There are limited treatment options available upon progression or recurrence of disease. Options often involve participation in clinical trials with promising new therapies. However, patients may not meet the strictly defined entry criteria to participate in these clinical trials. Under an Expanded Access (EA) program, we have treated 14 recurrent GBM patients with VAL-083, they were not eligible to participate in other clinical trials. The median time from last progression to start of VAL-083 was 1.0 month (95%CI:0.09-2.67). All patients had received chemoradiation with temozolomide. Five (5/14;36%) patients had ≥ 2 recurrences, 8/14 (57%) had multifocal disease, and the median KPS was 80 (95%CI:70-90). All patients had unmethylated MGMT promoter, 13/14 (93%) were IDH-WT, 9/14 (64%) had a TERT promoter mutation, 6/14 (43%) had a PTEN mutation, and 4/14 (28%) had an EGFR mutation. All patients received treatment with VAL-083 at 30 mg/m2 x 3 days every 21 days. Five patients with cerebral edema refractory to steroids received bevacizumab (BEV;10 mg/kg) concurrently with VAL-083, and 8 patients received dexamethasone (Dex; >4 mg/day) with VAL-083. This is the first report of the use of VAL-083 in combination with BEV (VAL-03/BEV).The main adverse event was thrombocytopenia consistent with prior experience. Four (4/14; 28%) patients had a dose reduction, 3 of which were due to thrombocytopenia. No patients had a dose reduction while receiving VAL-083/BEV. Two patients who progressed on VAL-083, were later treated with CCNU, and myelosuppression was not observed.Median progression-free survival (mPFS) and median overall survival (mOS) from last progression were 5.7 months (95%CI:1.3-7.9) and 8.3 months (95%CI:3.0-14.3), respectively. Additional treatment, safety and outcome data will be presented at the meeting.Clinicaltrials.gov Identifier: NCT03138629. EA treatment plans were approved by MD Anderson Cancer Center IRB." @default.
- W4309014865 created "2022-11-20" @default.
- W4309014865 creator A5008633199 @default.
- W4309014865 creator A5008768347 @default.
- W4309014865 creator A5013836305 @default.
- W4309014865 creator A5037535298 @default.
- W4309014865 creator A5065136823 @default.
- W4309014865 creator A5071489703 @default.
- W4309014865 creator A5087672907 @default.
- W4309014865 date "2022-11-01" @default.
- W4309014865 modified "2023-09-29" @default.
- W4309014865 title "DDDR-36. VAL-083 IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED UNDER EXPANDED ACCESS PROGRAM" @default.
- W4309014865 doi "https://doi.org/10.1093/neuonc/noac209.401" @default.
- W4309014865 hasPublicationYear "2022" @default.
- W4309014865 type Work @default.
- W4309014865 citedByCount "0" @default.
- W4309014865 crossrefType "journal-article" @default.
- W4309014865 hasAuthorship W4309014865A5008633199 @default.
- W4309014865 hasAuthorship W4309014865A5008768347 @default.
- W4309014865 hasAuthorship W4309014865A5013836305 @default.
- W4309014865 hasAuthorship W4309014865A5037535298 @default.
- W4309014865 hasAuthorship W4309014865A5065136823 @default.
- W4309014865 hasAuthorship W4309014865A5071489703 @default.
- W4309014865 hasAuthorship W4309014865A5087672907 @default.
- W4309014865 hasBestOaLocation W43090148651 @default.
- W4309014865 hasConcept C121332964 @default.
- W4309014865 hasConcept C126322002 @default.
- W4309014865 hasConcept C141071460 @default.
- W4309014865 hasConcept C142424586 @default.
- W4309014865 hasConcept C143998085 @default.
- W4309014865 hasConcept C197934379 @default.
- W4309014865 hasConcept C2776694085 @default.
- W4309014865 hasConcept C2777389519 @default.
- W4309014865 hasConcept C2777802072 @default.
- W4309014865 hasConcept C2780387249 @default.
- W4309014865 hasConcept C2780401358 @default.
- W4309014865 hasConcept C509974204 @default.
- W4309014865 hasConcept C535046627 @default.
- W4309014865 hasConcept C71924100 @default.
- W4309014865 hasConcept C87355193 @default.
- W4309014865 hasConcept C90924648 @default.
- W4309014865 hasConceptScore W4309014865C121332964 @default.
- W4309014865 hasConceptScore W4309014865C126322002 @default.
- W4309014865 hasConceptScore W4309014865C141071460 @default.
- W4309014865 hasConceptScore W4309014865C142424586 @default.
- W4309014865 hasConceptScore W4309014865C143998085 @default.
- W4309014865 hasConceptScore W4309014865C197934379 @default.
- W4309014865 hasConceptScore W4309014865C2776694085 @default.
- W4309014865 hasConceptScore W4309014865C2777389519 @default.
- W4309014865 hasConceptScore W4309014865C2777802072 @default.
- W4309014865 hasConceptScore W4309014865C2780387249 @default.
- W4309014865 hasConceptScore W4309014865C2780401358 @default.
- W4309014865 hasConceptScore W4309014865C509974204 @default.
- W4309014865 hasConceptScore W4309014865C535046627 @default.
- W4309014865 hasConceptScore W4309014865C71924100 @default.
- W4309014865 hasConceptScore W4309014865C87355193 @default.
- W4309014865 hasConceptScore W4309014865C90924648 @default.
- W4309014865 hasIssue "Supplement_7" @default.
- W4309014865 hasLocation W43090148651 @default.
- W4309014865 hasOpenAccess W4309014865 @default.
- W4309014865 hasPrimaryLocation W43090148651 @default.
- W4309014865 hasRelatedWork W2004862885 @default.
- W4309014865 hasRelatedWork W2079914139 @default.
- W4309014865 hasRelatedWork W2088650889 @default.
- W4309014865 hasRelatedWork W2156330848 @default.
- W4309014865 hasRelatedWork W2462822954 @default.
- W4309014865 hasRelatedWork W2527516493 @default.
- W4309014865 hasRelatedWork W2741288727 @default.
- W4309014865 hasRelatedWork W3004632817 @default.
- W4309014865 hasRelatedWork W4295758394 @default.
- W4309014865 hasRelatedWork W4385277635 @default.
- W4309014865 hasVolume "24" @default.
- W4309014865 isParatext "false" @default.
- W4309014865 isRetracted "false" @default.
- W4309014865 workType "article" @default.